Skip to main content
News > News > Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge

Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge

Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge


Minneapolis, MN and Bethesda, MD – July 26, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, is a winner of the Center for Advancing Innovation (CAI) Freedom from Cancer Startup Challenge (FCSC).

The FCSC, generously supported by the Laura and John Arnold Foundation and MedImmune®, has an overarching goal to advance more than one hundred inventions to prevent, diagnose and/or treat cancer. The inventions were developed at fifty-five institutions, including the National Institutes of Health (NIH).

Rosemarie Truman, CAI’s Founder and CEO, said, “The Freedom from Cancer Startup Challenge has been CAI’s most audacious initiative. The Challenge has united our nation’s brain trust against cancer by galvanizing the entrepreneurial, pharmaceutical, patient and academic communities.”

According to Jason E. Barkeloo, Founder and Chair of Open Therapeutics, “We are extremely proud to have achieved this important milestone. We could not have reached this point without CAI’s leadership. We are excited to advance these 27 inventions in our scientific collaboration platform that is freely available to researchers around the world.”

See below for the list of IP that Open Therapeutics will work to advance:


The Center for Advancing Innovation (CAI) is a global public-private partnership, non-profit focused on creating a virtuous circle of innovation and driving growth breakthroughs through novel, creative paradigms and models. CAI’s mission is to accelerate and increase the volume of research commercialization in support of high growth business to ignite entrepreneurship, bolster the global economy, and maximize the commercial and knowledge-based potential of promising inventions. CAI’s award-winning challenge-based accelerator, rigorous evidence-based due diligence, and capital-efficient lean management models serve to hyper-accelerate “gazelle” high-performing startups for outsized investor returns. For additional information about CAI, please visit

About Open Therapeutics LLC

Open Therapeutics ( is an intellectual property firm that creates and attracts therapeutic technologies and crowdsources them for use by the global scientific community. Researchers can freely access the intellectual properties, funding, lab equipment, manuscript development tool, and preprint server to further the development of the therapeutic technologies (medical devices, pharma, diagnostics) at Therapoid™ ( The Company is headquartered in Minneapolis, MN, with operations in Cincinnati, OH, Amman, Jordan, and Bangalore, India.


Contact: Jerome Hamilton, CEO, Open Therapeutics


Twitter: @OpenTherapeutic


We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange